Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study

Adv Neurol. 1996:69:467-73.

Authors

G Pizzolato¹, A Cagnin, A Rossato, F Chierichetti, M Fabbri, M Dam, G Ferlin, L Battistin

Affiliation

¹ Department of Neurology, University of Padova School of Medicine, Italy.

PMID: 8615167

No abstract available

Publication types

Clinical Trial

MeSH terms

Adult
Age of Onset
Aged
Aging / metabolism
Antiparkinson Agents / therapeutic use*
Disease Progression
Female
Humans
Iodine Radioisotopes
Levodopa / therapeutic use*
Male
Middle Aged
Neostriatum / diagnostic imaging
Neostriatum / drug effects
Neostriatum / metabolism*
Parkinson Disease / diagnostic imaging
Parkinson Disease / drug therapy*
Parkinson Disease / metabolism*
Receptors, Dopamine D2 / drug effects
Receptors, Dopamine D2 / metabolism*
Tomography, Emission-Computed, Single-Photon

Substances

Antiparkinson Agents
Iodine Radioisotopes
Receptors, Dopamine D2
Levodopa